Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ISIS 5132

Known as: ISIS 5132/CGP69846A, ISIS-5132, ISIS5132 
A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA. ISIS 5132 has been shown to specifically suppress… Expand
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Antineoplastic AgentsAntisense OligonucleotidesEnzyme InhibitorsThionucleotides

Narrower (1)

CGP 69846A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
An Oligonucleotide Transfection Vector Based on HSA and PDMAEMA Conjugation: Effect of Polymer Molecular Weight on Cell Proliferation and on Multicellular Tumor Spheroids.
A novel gene transfection vector was fabricated based on the conjugation of human serum albumin (HSA) and maleimide end… Expand
Is this relevant?
2009
2009
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
BACKGROUND A phase I trial was performed to evaluate the administration of carboplatin/paclitaxel in combination with ISIS-5132… Expand
Is this relevant?
2003
2003
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).
OBJECTIVE ISIS 5132 is a 20-base phosphorothioate DNA oligonucleotide against human c-raf kinase, a downstream effector of ras… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
PURPOSE Protein kinase C (PKC)-alpha and Raf-1 are important elements of proliferative signal transduction pathways in both… Expand
Is this relevant?
2002
2002
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
BACKGROUND Because treatment of metastatic colon cancer is noncurative, new treatments are needed. This trial evaluated the… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Raf-1 is a serine/threonine kinase that functions as a critical effector of Ras-mediated signal transduction via the mitogen… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2001
2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies…
Two multicentre phase II trials were designed to determine if tumour responses can be achieved in progressive small-cell lung… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
1999
1999
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
PURPOSE Raf-1 is a protein kinase that plays a broad role in oncogenic signaling and acts as a downstream effector of Ras in the… Expand
Is this relevant?
1999
1999
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
Abnormally regulated signaling through proliferative signal transduction pathways characterizes many of the common solid tumors… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE